Under the agreement, Affibody will design and develop affinity capture ligands for certain proteins specified by Agilent, using its Affibody technology. Agilent plans to incorporate these reagents into its protein removal technology for sample preparation. Eventually, Affibody will supply Agilent with production quantities of the reagents.
Affibody molecules are highly specific affinity proteins that mimic monoclonal antibodies. They are produced by combinatorial protein engineering applied on a proprietary scaffold.